Skip to main content
Clinical Trials/NCT04842162
NCT04842162
Recruiting
Phase 2

Study Evaluating Near-infrared Imaging Coupled With Indocyanine Green for Intraoperative Control of Resection Margins in ENT Surgery

Gustave Roussy, Cancer Campus, Grand Paris2 sites in 2 countries65 target enrollmentDecember 15, 2020

Overview

Phase
Phase 2
Intervention
indocyanine green
Conditions
Head and Neck Cancer
Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Enrollment
65
Locations
2
Primary Endpoint
Sensitivity of Near Infrared Fluorescence Imaging
Status
Recruiting
Last Updated
5 months ago

Overview

Brief Summary

Assess the sensitivity of real-time near-infrared fluorescence imaging to detect microscopic residual disease in the operating room after a complete macroscopic surgical resection of head and neck cancers

Registry
clinicaltrials.gov
Start Date
December 15, 2020
End Date
November 1, 2026
Last Updated
5 months ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Male or female 18 years of age or older
  • ECOG performance status 0-2
  • Histological confirmation of squamous cell carcinoma
  • Locating the primary tumour in the oral cavity or oropharynx
  • Disease operable for complete resection
  • Serum or urinary pregnancy test (as per centre practices) negative within 14 days prior to systemic indocyanin green injection (pre-operative visit), for women of childbearing age
  • Patient information and signed free and informed consent
  • Patient affiliated with a social security scheme or beneficiary of a similar scheme.
  • The patient must understand, sign and date the consent form prior to any protocol-specific procedures. The patient must be able and willing to comply with the study visits and procedures described in the protocol

Exclusion Criteria

  • Severe medical co-morbidities or contraindications to surgery
  • Primary tumour not operable
  • History of head and neck cancer in the past 5 years
  • History of radiation for head and neck cancer
  • Metastatic cancer
  • Tumours with necrosis ranges in pre-operative imaging
  • History of invasive cancer unless there has been no recurrence for more than 5 years with an exception for non-melanoma skin cancers.
  • Pregnant or nursing woman
  • Allergy or hypersensitivity to the product being administered (its active substance or other ingredients), iodized products or crustaceans.
  • Hyperthyroidism, thyroid adenoma, unifocal, multifocal or multinodular goiter of autoimmune origin.

Arms & Interventions

Patients with head and neck cancer

Intervention: indocyanine green

Outcomes

Primary Outcomes

Sensitivity of Near Infrared Fluorescence Imaging

Time Frame: at surgery

Sensitivity of real-time near-infrared fluorescence imaging to detect microscopic residual disease in the operating room after complete macroscopic surgical resection. For the calculation of the sensitivity, for each operating room we consider the first section and the last section in which the pathological analysis confirms the presence of microscopic residual disease. Patients for whom near-infrared fluorescence imaging detects disease are classified as true positives (TP). Sensitivity is defined as the number of TP divided by the total number of patients N.

Study Sites (2)

Loading locations...

Similar Trials